Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple <scp>CD38</scp> Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal?

Authors

Eirini Katodritou
Meera Mohan
Sabarinath Radhakrishnan
Rafeal Fonseca
Carolina Schinke

Institutions

Medical College of Wisconsin (US)
Theageneio General Hospital (GR)
Mayo Clinic in Arizona (US)
Mayo Clinic Hospital (US)
University of Arkansas for Medical Sciences (US)

Publication Details

Journal: American Journal of Hematology
Published: 2026-01-26
DOI: https://doi.org/10.1002/ajh.70215
Primary Topic: Multiple Myeloma Research and Treatments
Type: article
Field-Weighted Citation Impact: 0.00

Funders

Amgen
Bristol-Myers Squibb
Pfizer
Sanofi
Celgene
Regeneron Pharmaceuticals
Janssen Scientific Affairs
National Institutes of Health
Legend Biotech
National Cancer Institute

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal?

Eirini Katodritou, Meera Mohan, Sabarinath Radhakrishnan, Rafeal Fonseca et al.

Jan 26, 2026

American Journal of Hematology

Multiple Myeloma Research and Treatments

article

Reassessing the Duration of Induction Therapy for Newly Diagnosed, Transplant‐Eligible Myeloma Patients in the Context of Quadruple CD38 Monoclonal Antibody‐Based Regimens: Is 24 Weeks Optimal?

Eirini Katodritou, Meera Mohan, Sabarinath Radhakrishnan, Rafeal Fonseca, Carolina Schinke

January 26, 2026article en

Abstract

No abstract available for this paper.

American Journal of Hematology

Medical College of Wisconsin (US), Theageneio General Hospital (GR), Mayo Clinic in Arizona (US), Mayo Clinic Hospital (US), University of Arkansas for Medical Sciences (US)

Amgen, Bristol-Myers Squibb, Pfizer, Sanofi, Celgene, Regeneron Pharmaceuticals, Janssen Scientific Affairs, National Institutes of Health, Legend Biotech, National Cancer Institute

Good health and well-being

Openalex Percentile: Top 79%

Multiple Myeloma Research and Treatments

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.